Oxlumo Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Oxlumo market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to factors such as increased reimbursement and insurance coverage, positive clinical data and ongoing research, shifts in healthcare priorities, the lack of effective treatments for PH1, and enhanced diagnostic capabilities.

Growth during the market's forecast period can be driven by rising demand for non-invasive treatment options, increased government and institutional funding for rare diseases, growing patient awareness and advocacy, expanding market reach in emerging economies, and improvements in diagnostic techniques. Key trends in the forecast period include advancements in gene editing and CRISPR technology, the adoption of digital health tools and remote monitoring, the use of telemedicine for rare disease management, the integration of artificial intelligence (AI) in drug development, and innovations in RNA-based therapeutics.

The growing emphasis on personalized medicine is expected to drive the growth of the oxlumo market in the future. Personalized medicine is an approach that tailors treatment strategies based on an individual’s genetic makeup, lifestyle, and environmental factors to achieve the best possible results. This increased focus on personalized medicine is mainly due to advancements in genomics, which enable more precise and effective treatments based on a person’s genetic and lifestyle profile. Oxlumo (lumasiran) plays a role in personalized medicine by targeting specific genetic mutations in individuals with primary hyperoxaluria type 1 (PH1), a rare genetic disorder. It offers tailored treatment aimed at reducing oxalate production and preventing kidney damage according to a patient's genetic profile. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, up from six in 2022. Therefore, the rising focus on personalized medicine is fostering the growth of the oxlumo market.

The growing prevalence of primary hyperoxaluria is also expected to accelerate the oxlumo market’s growth. Primary hyperoxaluria is a rare genetic disorder that causes excessive oxalate production, potentially leading to kidney stones, kidney damage, and other complications. This disorder is linked to genetic mutations that hinder the body's ability to metabolize oxalate, resulting in its accumulation and possible kidney damage. Oxlumo helps manage primary hyperoxaluria by inhibiting the enzyme alanine-glyoxylate aminotransferase (AGT), which lowers oxalate production and reduces the risk of kidney damage. For example, in October 2024, Kidney Care UK, a UK-based nonprofit organization, stated that hyperoxaluria affects roughly 1 in 500,000 people in the UK, with type 1 being the most common, accounting for 80% of cases, and types 2 and 3 each representing around 10% of cases. Additionally, in October 2023, the National Center for Biotechnology Information (NCBI), a US-based medical library, reported that in Europe, PH1 has an estimated prevalence of 1 to 3 cases per million. Therefore, the increasing prevalence of primary hyperoxaluria is contributing to the growth of the oxlumo market.

A key trend in the oxlumo market is the development of innovative treatments such as RNA interference (RNAi) therapeutics, which offer enhanced options for treating genetic disorders. RNA interference therapy involves using small RNA molecules to silence or block specific gene expressions, providing a promising approach for treating genetic diseases. For instance, in October 2022, Alnylam Pharmaceuticals Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a label expansion for Oxlumo (lumasiran). This RNAi therapeutic is used to treat primary hyperoxaluria type 1 (PH1) by reducing urinary and plasma oxalate levels in both pediatric and adult patients. It works by silencing the HAO1 gene, decreasing oxalate production, and preventing complications associated with PH1.

The key company operating in the oxlumo market is Alnylam Pharmaceuticals Inc.

North America was the largest region in the oxlumo market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oxlumo report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oxlumo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oxlumo (lumasiran) is a medication prescribed for the treatment of primary hyperoxaluria type 1, a rare genetic disorder that leads to excessive oxalate production and subsequent kidney damage. It works by inhibiting the HOGA1 enzyme, which plays a key role in oxalate production. By reducing oxalate levels, Oxlumo helps prevent kidney stones and kidney failure. The medication is administered through a subcutaneous injection.

The primary types of clinical indications for oxlumo are primary hyperoxaluria type 1 (PH1), kidney stones, and end-stage renal disease (ESRD). Primary hyperoxaluria type 1 (PH1) is treated with Oxlumo (lumasiran), which reduces liver oxalate production to prevent kidney damage and failure. The medication is distributed through various channels, including retail pharmacies and online pharmacies, and is used by both pediatric and adult patients.

The oxlumo market research report is one of a series of new reports that provides oxlumo market statistics, including the oxlumo industry global market size, regional shares, competitors with the oxlumo market share, detailed oxlumo market segments, market trends, and opportunities, and any further data you may need to thrive in the oxlumo industry. This oxlumo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oxlumo market consists of sales of oxlumo (lumasiran) injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.